Stifel Financial Corp boosted its position in shares of Clovis Oncology, Inc. (NASDAQ:CLVS) by 29.6% during the 2nd quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 16,817 shares of the biopharmaceutical company’s stock after purchasing an additional 3,838 shares during the period. Stifel Financial Corp’s holdings in Clovis Oncology were worth $1,575,000 at the end of the most recent reporting period.
Other institutional investors also recently bought and sold shares of the company. Greenwood Capital Associates LLC boosted its holdings in Clovis Oncology by 4.0% in the second quarter. Greenwood Capital Associates LLC now owns 5,485 shares of the biopharmaceutical company’s stock worth $514,000 after purchasing an additional 212 shares in the last quarter. Sphera Funds Management LTD. acquired a new position in Clovis Oncology during the 2nd quarter worth $8,708,000. Boston Advisors LLC acquired a new position in Clovis Oncology during the 2nd quarter worth $8,332,000. UBS Asset Management Americas Inc. lifted its position in Clovis Oncology by 6.9% during the 1st quarter. UBS Asset Management Americas Inc. now owns 272,092 shares of the biopharmaceutical company’s stock worth $17,324,000 after acquiring an additional 17,450 shares during the last quarter. Finally, Federated Investors Inc. PA lifted its position in Clovis Oncology by 27.2% during the 2nd quarter. Federated Investors Inc. PA now owns 29,330 shares of the biopharmaceutical company’s stock worth $2,746,000 after acquiring an additional 6,265 shares during the last quarter. Institutional investors and hedge funds own 99.08% of the company’s stock.
ILLEGAL ACTIVITY NOTICE: This article was originally posted by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are viewing this article on another site, it was illegally copied and republished in violation of U.S. & international copyright and trademark legislation. The correct version of this article can be viewed at https://www.dispatchtribunal.com/2017/10/27/stifel-financial-corp-acquires-3838-shares-of-clovis-oncology-inc-clvs.html.
CLVS has been the topic of a number of analyst reports. Credit Suisse Group set a $107.00 price objective on shares of Clovis Oncology and gave the stock a “buy” rating in a research note on Tuesday, July 18th. Gabelli began coverage on shares of Clovis Oncology in a research note on Friday, July 7th. They set a “buy” rating and a $125.00 price objective on the stock. Zacks Investment Research raised shares of Clovis Oncology from a “hold” rating to a “buy” rating and set a $105.00 price target on the stock in a research note on Wednesday, July 12th. Royal Bank Of Canada began coverage on shares of Clovis Oncology in a research note on Thursday, September 14th. They set a “sector perform” rating and a $81.00 price target on the stock. Finally, Cann reissued a “hold” rating on shares of Clovis Oncology in a research note on Monday, September 11th. Eight analysts have rated the stock with a hold rating and fourteen have given a buy rating to the company. The company currently has an average rating of “Buy” and an average price target of $87.56.
Clovis Oncology, Inc. (NASDAQ CLVS) opened at 74.35 on Friday. The company has a 50-day moving average of $77.56 and a 200-day moving average of $72.03. The company’s market cap is $3.63 billion. Clovis Oncology, Inc. has a 52-week low of $25.81 and a 52-week high of $99.45.
Clovis Oncology (NASDAQ:CLVS) last released its quarterly earnings results on Wednesday, August 2nd. The biopharmaceutical company reported ($1.29) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($1.27) by ($0.02). The business had revenue of $14.62 million during the quarter, compared to analyst estimates of $13.07 million. The firm’s revenue for the quarter was down 32.5% on a year-over-year basis. During the same period in the prior year, the company posted ($2.07) EPS. On average, equities research analysts expect that Clovis Oncology, Inc. will post ($7.58) earnings per share for the current fiscal year.
In related news, Director James C. Blair sold 18,450 shares of the business’s stock in a transaction that occurred on Friday, August 4th. The stock was sold at an average price of $78.61, for a total transaction of $1,450,354.50. Following the completion of the transaction, the director now directly owns 2,185 shares in the company, valued at approximately $171,762.85. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. Also, insider Gillian C. Ivers-Read sold 3,000 shares of the company’s stock in a transaction that occurred on Friday, September 15th. The stock was sold at an average price of $69.50, for a total value of $208,500.00. Following the completion of the transaction, the insider now owns 191,583 shares of the company’s stock, valued at $13,315,018.50. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 27,450 shares of company stock valued at $2,122,625. 12.50% of the stock is currently owned by corporate insiders.
Clovis Oncology Profile
Clovis Oncology, Inc is a biopharmaceutical company focused on acquiring, developing and commercializing anti-cancer agents in the United States, Europe and other international markets. The Company’s product candidates include Rociletinib, Rubraca (Rucaparib) and Lucitanib. Rucaparib is an oral, small molecule poly adenosine diphosphate (ADP)-ribose polymerase (PARP) inhibitor of PARP1, PARP2 and PARP3 approved as a monotherapy for the treatment of patients with deleterious breast cancer (BRCA) (human genes associated with the repair of damaged deoxyribonucleic acid (DNA)) mutation (germline and/or somatic) associated advanced ovarian cancer.
Receive News & Ratings for Clovis Oncology Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Clovis Oncology Inc. and related companies with MarketBeat.com's FREE daily email newsletter.